Pembrolizumab Retreatment: Lessons from a Selected Group of Patients with Urothelial Carcinoma

被引：0
|
作者：
Zugman, Miguel [1 ]
Nguyen, Charles B. [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA
来源：
EUROPEAN UROLOGY | 2025年 / 87卷 / 04期
关键词：
D O I：
10.1016/j.eururo.2025.01.002
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：396 / 397
页数：2
相关论文
共 50 条
  • [21] Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
    Tomisaki, Ikko
    Harada, Mirii
    Sakano, Shigeru
    Terado, Michikazu
    Hamasuna, Ryoichi
    Harada, Shuji
    Matsumoto, Hiroomi
    Akasaka, Soichiro
    Nagata, Yujiro
    Minato, Akinori
    Harada, Ken-Ichi
    Fujimoto, Naohiro
    ANTICANCER RESEARCH, 2023, 43 (01) : 269 - 274
  • [22] FECAL MICROBIOTA PROFILING OF PATIENTS TREATED WITH NEOADJUVANT PEMBROLIZUMAB FOR MUSCLE INVASIVE UROTHELIAL CARCINOMA
    Pederzoli, Filippo
    Locatelli, Irene
    Riba, Michela
    Bandini, Marco
    Raggi, Daniele
    Marandino, Laura
    Alchera, Elisa
    Giannatempo, Patrizia
    Provero, Paolo
    Lazarevic, Dejan
    Luciano, Roberta
    Gallina, Andrea
    Briganti, Alberto
    Montorsi, Francesco
    Salonia, Andrea
    Necchi, Andrea
    Alfano, Massimo
    JOURNAL OF UROLOGY, 2021, 206 : E726 - E726
  • [23] Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
    Fukuokaya, Wataru
    Kimura, Takahiro
    Yanagisawa, Takafumi
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Koike, Yuhei
    Iwamoto, Yuya
    Enei, Yuki
    Tanaka, Masatoshi
    Urabe, Fumihiko
    Onuma, Hajime
    Honda, Mariko
    Miki, Jun
    Oyama, Yu
    Abe, Hirokazu
    Egawa, Shin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (01) : 229 - 236
  • [24] Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma
    Santoni, Matteo
    Rizzo, Alessandro
    Massari, Francesco
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2025,
  • [25] Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
    Wataru Fukuokaya
    Takahiro Kimura
    Takafumi Yanagisawa
    Shoji Kimura
    Shunsuke Tsuzuki
    Yuhei Koike
    Yuya Iwamoto
    Yuki Enei
    Masatoshi Tanaka
    Fumihiko Urabe
    Hajime Onuma
    Mariko Honda
    Jun Miki
    Yu Oyama
    Hirokazu Abe
    Shin Egawa
    Targeted Oncology, 2021, 16 : 189 - 196
  • [26] Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
    Fukuokaya, Wataru
    Kimura, Takahiro
    Yanagisawa, Takafumi
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Koike, Yuhei
    Iwamoto, Yuya
    Enei, Yuki
    Tanaka, Masatoshi
    Urabe, Fumihiko
    Onuma, Hajime
    Honda, Mariko
    Miki, Jun
    Oyama, Yu
    Abe, Hirokazu
    Egawa, Shin
    TARGETED ONCOLOGY, 2021, 16 (02) : 189 - 196
  • [27] Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
    Wataru Fukuokaya
    Takahiro Kimura
    Takafumi Yanagisawa
    Shoji Kimura
    Shunsuke Tsuzuki
    Yuhei Koike
    Yuya Iwamoto
    Yuki Enei
    Masatoshi Tanaka
    Fumihiko Urabe
    Hajime Onuma
    Mariko Honda
    Jun Miki
    Yu Oyama
    Hirokazu Abe
    Shin Egawa
    Cancer Immunology, Immunotherapy, 2022, 71 : 229 - 236
  • [28] Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.
    Castellano, Daniel E.
    Balar, Arjun Vasant
    O'Donnell, Peter H.
    Grivas, Petros
    Vaughn, David J.
    Powles, Thomas
    Vuky, Jacqueline
    Lee, Jae-Lyun
    Fradet, Yves
    Bellmunt, Joaquim
    Angel Climent, Miguel
    Vogelzang, Nicholas J.
    Plimack, Elizabeth R.
    Gurney, Howard
    Hahn, Noah M.
    Sternberg, Cora N.
    Xu, Jin Zhi
    Imai, Kentaro
    Moreno, Blanca Homet
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] Efficacy of pembrolizumab as second line therapy for advanced urothelial carcinoma
    Nouhaud, F. -X.
    PROGRES EN UROLOGIE, 2017, 27 (02): : F38 - F39
  • [30] Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma
    Sundahl, N.
    Rottey, S.
    Decaestecker, K.
    De Visschere, P.
    De Maeseneer, D.
    Reynders, D.
    Meireson, A.
    Goetghebeur, E.
    Fonteyne, V.
    Verbeke, S.
    Brochez, L.
    Ost, P.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S357 - S358
12345